CADD522

CADD522 is a small molecule inhibitor of runt-related transcription factor 2 (RUNX2)-DNA binding. Originally identified through computer-assisted drug discovery (CADD) at the University of Maryland, CADD522 blocks the interaction between RUNX2 and DNA, thereby downregulating the transcription of downstream target genes such as matrix metalloproteinase-13 (MMP-13), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT1). It has demonstrated preclinical efficacy in suppressing breast cancer growth, tumorsphere formation, and metastasis in vivo. Additionally, research from the University of East Anglia has shown that CADD522 can stimulate bone formation and improve bone microarchitecture in post-menopausal osteoporosis models, while also reducing body fat and reversing metabolic changes associated with menopause.

Other names

3-((3,4-dichlorophenyl)carbamoyl)bicyclohept-5-ene-2-carboxylic acid3-[[(3,4-dichlorophenyl)amino]carbonyl]-bicyclohept-5-ene-2-carboxylic acidCADD-522CADD522CADD 522